Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B
Seeking Alpha News (Wed, 25-Mar 12:31 PM ET)
Globe Newswire (Tue, 17-Mar 12:01 PM ET)
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
Globe Newswire (Thu, 12-Mar 8:30 PM ET)
Market Chameleon (Thu, 12-Mar 3:50 AM ET)
Indivior Announces Proposed Convertible Senior Notes Offering
Globe Newswire (Thu, 12-Mar 7:00 AM ET)
Globe Newswire (Wed, 11-Mar 9:00 AM ET)
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results
Globe Newswire (Thu, 26-Feb 7:00 AM ET)
Indivior to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 24-Feb 7:00 AM ET)
Globe Newswire (Wed, 28-Jan 7:00 AM ET)
Indivior Announces Completion of Redomiciliation to the United States
Globe Newswire (Mon, 26-Jan 7:00 AM ET)
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Indivior Pharmaceuticals trades on the NASDAQ stock market under the symbol INDV.
As of March 25, 2026, INDV stock price climbed to $30.26 with 2,048,553 million shares trading.
INDV has a beta of 0.70, meaning it tends to be less sensitive to market movements. INDV has a correlation of 0.06 to the broad based SPY ETF.
INDV has a market cap of $3.78 billion. This is considered a Mid Cap stock.
Last quarter Indivior Pharmaceuticals reported $358 million in Revenue and $.82 earnings per share. This beat revenue expectation by $53 million and exceeded earnings estimates by $.16.
The top ETF exchange traded funds that INDV belongs to (by Net Assets): IJR, IWM, VXF, XSMO, SPSM.
INDV has outperformed the market in the last year with a return of +199.6%, while the SPY ETF gained +15.7%. However, in the most recent history, INDV shares have underperformed the stock market with its stock returning -16.3% in the last 3 month period and -9.2% for the last 2 week period, while SPY has returned -4.6% and -2.7%, respectively.
INDV support price is $27.79 and resistance is $29.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INDV shares will trade within this expected range on the day.